SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
   Trade name: Lisinopril Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
   Use of the Substance/Mixture: Pharmaceutical

1.3 Details of the supplier of the safety data sheet
   Company: MSD
   Shotton Lane
   NE23 3JU Cramlington NU - Great Britain
   Telephone: 44 1 670 59 30 00
   Telefax: 908-735-1496
   E-mail address of person responsible for the SDS: EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
   1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
   Classification (REGULATION (EC) No 1272/2008)
   Reproductive toxicity, Category 1A  H360D: May damage the unborn child.

2.2 Label elements
   Labelling (REGULATION (EC) No 1272/2008)
   Hazard pictograms:
   Signal word: Danger
   Hazard statements: H360D May damage the unborn child.
   Precautionary statements: Prevention:
   P201 Obtain special instructions before use.
   P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.
   Response:
P308 + P313  IF exposed or concerned: Get medical advice/attention.

Storage:
P405  Store locked up.

Hazardous components which must be listed on the label:
Lisinopril

2.3 Other hazards
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lisinopril</td>
<td>83915-83-7</td>
<td>Repr. 1A; H360D</td>
<td></td>
</tr>
</tbody>
</table>
<pre><code>                  |          | STOT RE 2; H373 (Kidney) | &gt;= 1 - &lt; 10 |
</code></pre>

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled: If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact: If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Lisinopril Formulation

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed
Risks: May damage the unborn child.
Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.

4.3 Indication of any immediate medical attention and special treatment needed
Treatment: Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media
Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

5.2 Special hazards arising from the substance or mixture
Specific hazards during firefighting: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides
Metal oxides
Oxides of phosphorus

5.3 Advice for firefighters
Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.
SEASON 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up: Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling: Do not get on skin or clothing. Do not breathe dust. Do not swallow. Avoid contact with eyes. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed. Minimize dust generation and accumulation.
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Lisinopril Formulation

Version 2.4
Revision Date: 01.10.2020
SDS Number: 51803-00016
Date of last issue: 23.03.2020
Date of first issue: 26.01.2015

Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures:
If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

7.2 Conditions for safe storage, including any incompatibilities
Requirements for storage areas and containers:
Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Advice on common storage:
Do not store with the following product types:
Strong oxidizing agents
Organic peroxides
Explosives
Gases

7.3 Specific end use(s)
Specific use(s):
No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Starch</td>
<td>9005-25-8</td>
<td>TWA (inhalable dust)</td>
<td>10 mg/m3</td>
<td>GB EH40</td>
</tr>
</tbody>
</table>

Further information: For the purposes of these limits, respirable dust and inhalable dust are those fractions of airborne dust which will be collected when sampling is undertaken in accordance with the methods described in MDHS14/4 General methods for sampling and gravimetric analysis or respirable, thoracic and inhalable aerosols., The COSHH definition of a substance hazardous to health includes dust of any kind when present at a concentration in air equal to or greater than 10 mg.m⁻³ 8-hour TWA of inhalable dust or 4 mg.m⁻³ 8-hour TWA of respirable dust. This means that any dust will be subject to COSHH if people are exposed to dust above these levels. Some dusts have been assigned specific WELs and exposure to these must comply with the appropriate limits., Most industrial dusts contain particles of a wide range of sizes. The behaviour, deposition and fate of any particular particle after entry into the human respiratory system, and the body response that it elicits, depend on the nature and size of the particle. HSE distinguishes two size fractions for limit-setting purposes termed 'inhalable' and 'respirable'. Inhalable dust approximates to the fraction of airborne material that enters the nose and mouth during breathing and is therefore available for deposition in the respiratory tract. Respirable dust approximates to the fraction that penetrates to the gas exchange region of the lung. Fuller definitions and explanatory
material are given in MDHS14/4., Where dusts contain components that have their own assigned WEL, all the relevant limits should be complied with., Where no specific short-term exposure limit is listed, a figure three times the long-term exposure limit should be used.

<table>
<thead>
<tr>
<th>TWA (Respirable dust)</th>
<th>4 mg/m³</th>
</tr>
</thead>
<tbody>
<tr>
<td>GB EH40</td>
<td></td>
</tr>
</tbody>
</table>

Further information: For the purposes of these limits, respirable dust and inhalable dust are those fractions of airborne dust which will be collected when sampling is undertaken in accordance with the methods described in MDHS14/4 General methods for sampling and gravimetric analysis or respirable, thoracic and inhalable aerosols., The COSHH definition of a substance hazardous to health includes dust of any kind when present at a concentration in air equal to or greater than 10 mg.m⁻³ 8-hour TWA of inhalable dust or 4 mg.m⁻³ 8-hour TWA of respirable dust. This means that any dust will be subject to COSHH if people are exposed to dust above these levels. Some dusts have been assigned specific WELs and exposure to these must comply with the appropriate limits., Most industrial dusts contain particles of a wide range of sizes. The behaviour, deposition and fate of any particular particle after entry into the human respiratory system, and the body response that it elicits, depend on the nature and size of the particle. HSE distinguishes two size fractions for limit-setting purposes termed ‘inhalable’ and ‘respirable’. Inhalable dust approximates to the fraction of airborne material that enters the nose and mouth during breathing and is therefore available for deposition in the respiratory tract. Respirable dust approximates to the fraction that penetrates to the gas exchange region of the lung. Fuller definitions and explanatory material are given in MDHS14/4., Where dusts contain components that have their own assigned WEL, all the relevant limits should be complied with., Where no specific short-term exposure limit is listed, a figure three times the long-term exposure limit should be used.

<table>
<thead>
<tr>
<th>Lisinopril 83915-83-7</th>
<th>TWA</th>
<th>20 µg/m³ (OEB 3)</th>
<th>Internal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wipe limit</td>
<td>200 µg/100 cm²</td>
<td>Internal</td>
<td></td>
</tr>
</tbody>
</table>

**8.2 Exposure controls**

**Engineering measures**

Minimize workplace exposure concentrations.
Apply measures to prevent dust explosions.
Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).
If sufficient ventilation is unavailable, use with local exhaust ventilation.

**Personal protective equipment**

**Eye protection**

- Wear the following personal protective equipment:
  - Safety goggles
  - Equipment should conform to BS EN 166

**Hand protection**

**Material**

- Chemical-resistant gloves

**Remarks**

- Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not
determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Skin and body protection: Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential. Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Equipment should conform to BS EN 143

Filter type: Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance</td>
<td>powder</td>
</tr>
<tr>
<td>Colour</td>
<td>No data available</td>
</tr>
<tr>
<td>Odour</td>
<td>odourless</td>
</tr>
<tr>
<td>Odour Threshold</td>
<td>No data available</td>
</tr>
<tr>
<td>pH</td>
<td>No data available</td>
</tr>
<tr>
<td>Melting point/freezing point</td>
<td>No data available</td>
</tr>
<tr>
<td>Initial boiling point and boiling range</td>
<td>No data available</td>
</tr>
<tr>
<td>Flash point</td>
<td>No data available</td>
</tr>
<tr>
<td>Evaporation rate</td>
<td>No data available</td>
</tr>
<tr>
<td>Flammability (solid, gas)</td>
<td>May form explosive dust-air mixture during processing, handling or other means.</td>
</tr>
<tr>
<td>Upper explosion limit / Upper flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Lower explosion limit / Lower flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Vapour pressure</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative vapour density</td>
<td>No data available</td>
</tr>
<tr>
<td>Density</td>
<td>No data available</td>
</tr>
<tr>
<td>Solubility(ies)</td>
<td>Water solubility</td>
</tr>
<tr>
<td></td>
<td>No data available</td>
</tr>
<tr>
<td>Partition coefficient: n-octanol/water</td>
<td>No data available</td>
</tr>
</tbody>
</table>
Lisinopril Formulation

9.2 Other information

Flammability (liquids) : No data available
Molecular weight : No data available
Particle size : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.

10.4 Conditions to avoid
Heat, flames and sparks. Avoid dust formation.

10.5 Incompatible materials
Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects
Inhalation
Skin contact
Ingestion
Eye contact
Lisinopril Formulation

Acute toxicity
Not classified based on available information.

Components:

Lisinopril:
Acute oral toxicity: LD50 (Rat): > 20,000 mg/kg
LD50 (Mouse): > 20,000 mg/kg

Skin corrosion/irritation
Not classified based on available information.

Components:

Lisinopril:
Species: Rabbit
Result: Mild skin irritation

Serious eye damage/eye irritation
Not classified based on available information.

Components:

Lisinopril:
Species: Rabbit
Result: Mild eye irritation

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:

Lisinopril:
Test Type: Maximisation Test
Exposure routes: Dermal
Result: negative

Germ cell mutagenicity
Not classified based on available information.

Components:

Lisinopril:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster lung cells
Result: negative

Test Type: Alkaline elution assay
Test system: rat hepatocytes
Result: negative

Genotoxicity in vivo
Test Type: Micronucleus test
Species: Mouse
Application Route: Oral
Result: negative

Carcinogenicity
Not classified based on available information.

Components:

Lisinopril:
Species: Rat
Application Route: Oral
Exposure time: 105 weeks
NOAEL: 90 mg/kg body weight
Result: negative

Species: Mouse
Application Route: Oral
Exposure time: 92 weeks
NOAEL: 135 mg/kg body weight
Result: negative

Reproductive toxicity
May damage the unborn child.

Components:

Lisinopril:
Effects on fertility
Test Type: Fertility
Species: Rat
Application Route: Oral
Fertility: NOAEL: 300 mg/kg body weight
Symptoms: No effects on mating performance
Result: Animal testing did not show any effects on fertility.

Effects on foetal development
Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 30 mg/kg body weight
Result: positive, No teratogenic effects

Species: Mouse
Application Route: Oral
Developmental Toxicity: LOAEL: 100 mg/kg body weight
Lisinopril Formulation

Symptoms: Total Resorptions / resorption rate
Result: Embryotoxic effects and adverse effects on the offspring were detected.

Test Type: Development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: LOAEL: 0.1 mg/kg body weight
Result: Embryotoxic effects and adverse effects on the offspring were detected.

Represervative toxicity - Assessment: Positive evidence of adverse effects on development from human epidemiological studies.

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
Not classified based on available information.

Components:

Lisinopril:
Exposure routes: Ingestion
Target Organs: Kidney
Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity
Components:

Lisinopril:
Species: Rat
LOAEL: < 3,650 mg/kg
Application Route: Oral
Exposure time: 1 yr
Target Organs: Kidney

Species: Dog
LOAEL: < 840 mg/kg
Application Route: Oral
Exposure time: 4 Weeks
Target Organs: Kidney

Aspiration toxicity
Not classified based on available information.

Experience with human exposure
Components:

Lisinopril:
Ingestion: Symptoms: Dizziness, Headache, Fatigue, Diarrhoea, Nau---
SECTION 12: Ecological information

12.1 Toxicity

**Components:**

**Lisinopril:**
- Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 20,000 mg/l
  - Exposure time: 48 h
  - Method: OECD Test Guideline 202

12.2 Persistence and degradability
No data available

12.3 Bioaccumulative potential
No data available

12.4 Mobility in soil
No data available

12.5 Results of PBT and vPvB assessment
Not relevant

12.6 Other adverse effects
No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

**Product:**
- Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

**Contaminated packaging:**
- Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number
Not regulated as a dangerous good

14.2 UN proper shipping name
Not regulated as a dangerous good

14.3 Transport hazard class(es)
Not regulated as a dangerous good
**SAFETY DATA SHEET**

according to Regulation (EC) No. 1907/2006

**Lisinopril Formulation**

**Version** 2.4  
**Revision Date:** 01.10.2020  
**SDS Number:** 51803-00016  
**Date of last issue:** 23.03.2020  
**Date of first issue:** 26.01.2015

14.4 **Packing group**  
Not regulated as a dangerous good

14.5 **Environmental hazards**  
Not regulated as a dangerous good

14.6 **Special precautions for user**  
Not applicable

14.7 **Transport in bulk according to Annex II of Marpol and the IBC Code**  
Remarks: Not applicable for product as supplied.

**SECTION 15: Regulatory information**

15.1 **Safety, health and environmental regulations/legislation specific for the substance or mixture**

- REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII): Not applicable
- REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59): Not applicable
- REACH - List of substances subject to authorisation (Annex XIV): Not applicable
- Regulation (EC) No 1005/2009 on substances that deplete the ozone layer: Not applicable
- Regulation (EU) 2019/1021 on persistent organic pollutants (recast): Not applicable
- Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals: Not applicable

**Other regulations:**

- Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.
- Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

**The components of this product are reported in the following inventories:**

- **AICS**: not determined
- **DSL**: not determined
- **IECSC**: not determined

15.2 **Chemical safety assessment**  
A Chemical Safety Assessment has not been carried out.

**SECTION 16: Other information**

**Other information**: Items where changes have been made to the previous version
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Lisinopril Formulation

Version 2.4
Revision Date: 01.10.2020
SDS Number: 51803-00016
Date of last issue: 23.03.2020
Date of first issue: 26.01.2015

are highlighted in the body of this document by two vertical lines.

Full text of H-Statements
H360D : May damage the unborn child.
H373 : May cause damage to organs through prolonged or repeated exposure if swallowed.

Full text of other abbreviations
Repr. : Reproductive toxicity
STOT RE : Specific target organ toxicity - repeated exposure
GB EH40 : UK. EH40 WEL - Workplace Exposure Limits
GB EH40 / TWA : Long-term exposure limit (8-hour TWA reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Classification of the mixture: Classification procedure:
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

GB / EN